Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

This trial is testing a new combination of a checkpoint inhibitor drug (SHR-1316, given under the skin) plus standard chemotherapy (carboplatin and etoposide) as a first-line treatment for extensive-stage small cell lung cancer — a fast-growing form of lung cancer that has spread beyond one lung. **You may be eligible if...** - You have been diagnosed with extensive-stage small cell lung cancer confirmed by biopsy - You have not yet received chemotherapy or immunotherapy for this cancer - You are in good physical condition and have at least one measurable tumor - Your kidneys, liver, and bone marrow are working adequately **You may NOT be eligible if...** - You have previously received any systemic treatment for small cell lung cancer - Cancer has spread to the brain (or you have uncontrolled brain metastases) - You have serious autoimmune disease or are on long-term steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.